Madrigal Pharmaceuticals

Madrigal Pharmaceuticals

Pharmaceutical Manufacturing

Madrigal is focused on developing therapeutics to improve the lives of patients with metabolic and fatty liver diseases.

Über uns

Madrigal (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). Our first therapy was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis. For more information, visit www.madrigalpharma.com.

Website
https://www.madrigalpharma.com/
Industrie
Pharmaceutical Manufacturing
Größe des Unternehmens
201-500 Mitarbeiter
Hauptsitz
Conshohocken, Pennsylvania
Typ
Öffentliches Unternehmen
Gegründet
2016
Spezialitäten
Liver Disease, NASH, Metabolic Disease, and MASH

Standorte

Aktualisierungen

Ähnliche Seiten

Jobs durchsuchen

Finanzierung

Madrigal Pharmaceuticals 8 total rounds

Letzte Runde

Eigenkapital nach dem IPO

US$ 690.0M

Siehe mehr Informationen auf crunchbase